Poster abstracts 57 being used by 40 % of pts PTC and 12 % of pts who had EP. Only 41 % pts who had EP informed the healthcare provider( HCP) treating their PS of their pregnancy right away, while 21 % did not notify them at all. While PTC, most pts who had not EP( 88 %), sought FP advice from the internet; only 21 % had consulted the HCP treating their PS, compared to 55 % of pts who had EP. Of the 96 pts who discussed FP with the HCP treating their PS, just 7 % said this was initiated by the HCP. Pts PTC were most influenced by their personal network( e. g. family), but of pts who had EP, 41 % said the HCP treating their PS was one of the most influential types of support in their FP decisions. Pts reported wanting information on the impact of PS and treatments on their baby, the heritability of PS, and flare management during pregnancy. During pregnancy, 65 % pts who had EP stopped treatment( of any type), 79 % of whom did so out of fear of harming their baby. In 40 % cases where pts had stopped all and any treatment for PSO, the decision was initiated by the pt, and in 47 %, by their PS treatment provider. Of pts who stopped treatment, 44 % experienced a worsening in the severity of their PS, yet most pts do / did not have a plan for flare management during pregnancy( PTC: 69 %; EP: 65 %). Many pts stopping all treatment had not been advised on restarting treatment post-partum( PTC: 42 %; EP: 23 %). Conclusions: Many WoCP with PS take systemic medications but many do not discuss FP with their PS treatment provider, and if they do, the discussion is rarely initiated by the HCP. PS treatment providers should prioritize discussing FP, and plan treatment around and during pregnancy. The educational needs of WoCP with PS include the impact of treatment on their baby, flare management during pregnancy, and restarting treatment post-partum. Acknowledgements: This study was funded by UCB Pharma. The survey was conducted by the National Psoriasis Foundation. We thank the patients who contributed to this study. Editorial services were provided by Costello Medical.
P140 THE PSYCHOSOCIAL IMPACT OF PSORIASIS: DIFFERENTIAL EXPERIENCES OF MEN AND WOMEN
IN EARLY ADULTHOOD Caitriona Ryan 1, Carl Vandeloo 2, Duncan Munro 3, Alvaro Arjona 1
1
Blackrock Clinic, Dublin, Ireland and University College, Dublin, Ireland,
2
UCB Pharma, Brussels, Belgium, 3 Cello Health, London, UK
Introduction: Plaque psoriasis( PSO) can have a profound impact on patients’( pts’) psychosocial wellbeing, leading to selfconsciousness, embarrassment, depression, social isolation and stigmatization. However, little is known of how the impact of disease differs between genders. Objective: To evaluate differences in the psychosocial impact of PSO on quality of life in men and women in early adulthood. Methods: Pts aged ≥18 in the US, Canada, France, Germany and Italy without a diagnosis of psoriatic arthritis were invited to complete a postal survey( Oct 2016 – Jan 2017), in the ratio 3:1 as being treated with advanced therapy( biologic / apremilast), or eligible for but not yet receiving advanced therapy. Answers were given on 5- or 7-point Likert Scale. Percentages shown are proportions of pts responding using either of the two responses indicating greatest impact of disease. Data are presented for pts in early adulthood( 18 – 45 years),[ 1 ] stratified by gender. Results: 63 women and 73 men completed the survey; mean age was 35 and 36 years, respectively, mean age at diagnosis was 28 for both genders. Disease distribution was similar between genders, although women reported more severe disease affecting their arms and males reported more severe scalp disease. Whilst physical impacts of disease were similar( ≤ 2 pts reported severe problems with walking, washing / dressing, carrying out housework / family / leisure activities or daily work), a higher proportion of women( 14 % vs 4 %) reported severe / extreme pain or discomfort. Both genders were more concerned by appearance( women: 73 %, men: 63 %) than pain( women: 43 %, men: 34 %). A higher proportion of women than men were concerned by their appearance( 73 % vs 63 %), reported a greater impact on their choice of clothing( 37 % vs 21 %), and always / usually tried to cover their skin( 27 % vs 16 %). Similarly, psychosocial effects of disease tended to be greater in women: 16 % women vs 8 % men reported severe / extreme anxiety or depression; 29 % women vs 18 % men suffered sexually / in achieving intimacy. Similar proportions had suffered at work( women: 11 %, men: 16 %), while a higher proportion of women( 6 %) than men( 3 %) struggled to live their lives as they did prior to their diagnosis. These findings have been corroborated by ethnography studies. Conclusion: Despite similar clinical manifestations of PSO, women in early adulthood tended to report a greater impact of their disease on their lives, both physically, in terms of pain, and psychosocially, in terms of effects on relationships and impact on their daily lives. Physician awareness of such gender differences in the impact of the disease on patients’ lives would encourage a more holistic approach to discussing treatment options with their patients. Reference: 1. A Conception of Adult Development. Daniel J. Levinson. 1986. American Psychologist vol. 41, No. 1, 3-13
P141 CERTOLIZUMAB PEGOL IMPROVES PATIENT- REPORTED OUTCOMES IN CHRONIC PLAQUE
PSORIASIS OVER 1 YEAR Diamant Thaçi 1, Alice B Gottlieb 2, Kristian Reich 3, Jerry Bagel 4, Luke Peterson 5, Oana Purcaru 6, Jolanta Węgłowska 7
1
University Hospital of Schleswig-Holstein Campus Lübeck, Lübeck, Germany, 2 Department of Dermatology, New York Medical College at Metropolitan Hospital, NY, NY, 3 SCIderm Research Institute, Hamburg, and Dermatologikum Berlin, Germany, 4 Psoriasis Treatment Center of Central New Jersey, East Windsor, NJ, 5 UCB Pharma, Raleigh, NC, USA, 6 UCB Pharma, Brussels, Belgium, 7 Niepubliczny Zakład Opieki Zdrowotnej multiMedica, Wrocław, Poland
Introduction: Certolizumab pegol( CZP) is an Fc-free, PEGylated, anti-TNF biologic. Here we present patient( pt)-reported quality of life( QoL), work productivity and social activities over 48 weeks of CZP treatment. Materials / Methods: Data were pooled from CIMPASI-1( NCT02326298) and CIMPASI-2( NCT02326272) phase 3 trials of adults with PSO ≥6 months( psoriasis area and severity index [ PASI ] ≥12, affected body surface area [ BSA ] ≥10 %, physician’ s global assessment [ PGA ] ≥3 / 5). Pts were randomized to CZP 400 mg every 2 weeks( Q2W), CZP 200 mg Q2W( following 400 mg loading dose at Weeks 0, 2, 4), or placebo( PBO) Q2W for 16 weeks. Week 16 CZP-treated PASI 50 responders continued initial blinded treatment to Week 48( PBO-treated PASI 50 responders are not included). PASI 50 non-responders at Weeks 32, 40 and 48 were discontinued. Mean change from baseline( CFB) in Dermatology Life Quality Index( DLQI), rates for DLQI minimally clinically important difference( MCID; ≥4-point improvement) and DLQI remission( score of 0 / 1), and CFB in Work Productivity and Activity Impairment( WPAI) PSO-specific at Weeks 16 and 48 were assessed. Negative CFB for DLQI and WPAI signifies improvement. CFB DLQI analyses used last observation carried forward( LOCF) imputation for missing data, DLQI MCID and remission analyses used nonresponder imputation, WPAI analyses used last observation carried forward imputation at Week 16 and observed data at Week 48. Results: At Week 16, CZP pts showed greater improvements in DLQI vs PBO, and higher proportions achieved DLQI MCID and DLQI remission( Table). Improvements were maintained to Week 48 in CZP-treated pts who continued treatment( Table). Improve-
Acta Derm Venereol 2018